Cargando…
Inclusion Body Myositis Treated with Alemtuzumab
Inclusion body myositis (IBM) is a chronic inflammatory myopathy with a progressive course. It is more common in the later years of life and usually presents with limb weakness. We present the case of a patient who developed proximal weakness in the lower limbs and, four years later, facial asymmetr...
Autores principales: | Sá, Juliana, Costelha, João, Marinho, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936915/ https://www.ncbi.nlm.nih.gov/pubmed/31893209 http://dx.doi.org/10.12890/2019_001368 |
Ejemplares similares
-
Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010) -
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009) -
Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013) -
Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017) -
Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)